MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/tp.0b013e318188af15

Медицинская библиотека · Transplantation · 2008

Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.

Offner Gisela, Toenshoff Burkhard, Höcker Britta, Krauss Manuela, Bulla Monika, Cochat Pierre, Fehrenbach Henry, Fischer Wolfgang, Foulard Michel, Hoppe Bernd, Hoyer Peter F, Jungraithmayr Therese C, Klaus Günter, Latta Kay, Leichter Heinz, Mihatsch Michael J, Misselwitz Joachim, Montoya Carmen, Müller-Wiefel Dirk E, Neuhaus Thomas J, Pape Lars, Querfeld Uwe, Plank Christian, Schwarke Dieter, Wygoda Simone, Zimmerhackl Lothar B

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Basiliximab, a monoclonal CD25 antibody has proofed effective in reducing acute rejection episodes in adults in various immunosuppressive regimens. The effect of basiliximab in the pediatric population is controversial.

METHODS

In a 12-month, double-blind, placebo-controlled trial, renal transplant patients aged 1 to 18 years were randomized to basiliximab or placebo with cyclosporine microemulsion, mycophenolate mofetil, and corticosteroids. The intent-to-treat population comprised 192 patients (100 basiliximab and 92 placebo).

RESULTS

The primary efficacy endpoint, time to first biopsy-proven acute rejection episode, or treatment failure by month 6, occurred in 16.7% of basiliximab-treated patients and 21.7% of placebo-treated patients (Kaplan-Meier estimates; hazard ratio 0.72, two-sided 90% confidence interval 0.416-1.26, n.s.). The rate and severity of subclinical rejections in protocol biopsies performed at 6 months posttransplant was higher in the basiliximab group (25.0%) than in the placebo group (11.7%). Patient and death-censored graft survival at 12 months was 97% and 99%, respectively, in the basiliximab cohort, and 100% and 99% among placebo-treated patients (n.s.). Renal function was similar in both treatment groups, and there were no significant between-treatment differences in the incidence of adverse events or infections.

CONCLUSIONS

Addition of basiliximab induction to a regimen of cyclosporine microemulsion, mycophenolate mofetil, and steroids resulted in a numerically lower but not significant incidence of biopsy-proven acute rejection versus placebo and excellent graft and patient survival at 1 year in pediatric renal transplant recipients. Whether this numerical difference is a true therapeutic benefit in view of the higher rate and severity of subclinical rejections in the basiliximab group in the protocol biopsy will be investigated in a long-term follow-up study.

Для цитирования: Offner Gisela, Toenshoff Burkhard, Höcker Britta, Krauss Manuela, Bulla Monika, Cochat Pierre, Fehrenbach Henry, Fischer Wolfgang, Foulard Michel, Hoppe Bernd, Hoyer Peter F, Jungraithmayr Therese C, Klaus Günter, Latta Kay, Leichter Heinz, Mihatsch Michael J, Misselwitz Joachim, Montoya Carmen, Müller-Wiefel Dirk E, Neuhaus Thomas J, Pape Lars, Querfeld Uwe, Plank Christian, Schwarke Dieter, Wygoda Simone, Zimmerhackl Lothar B. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.. Transplantation. 2008. DOI: 10.1097/tp.0b013e318188af15.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.